EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design

Macarena P Quintana-Hayashi, Kathleen Connolly, Marcus Millegård, Chandrali Bhattacharya, Magnus Åstrand, Michelle Turton, Patricia Ely Pizzato, James L Januzzi, Jaya B Rosenmeier iD

ESC Heart Failure · 2026

DOI: 10.1093/eschf/xvaf007 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESC Heart Failure, 2026. Verfasst von Macarena P Quintana-Hayashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Ventricular Function, Left, Receptors, Peptide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

AZD5462 is the first oral relaxin family peptide receptor 1 agonist in clinical development and is expected to reduce systemic vascular resistance and afterload and to increase natriuresis, decreasing circulating blood volume, benefitting patients with chronic heart failure (HF). LUMINARA is a Phase 2b study of the efficacy and safety of AZD5462 in participants with broad HF. Study design This randomized, placebo-controlled, double-blind, multi-centre, dose-ranging study will include ∼360 participants with HF: 220 with left ventricular ejection fraction (LVEF) ≤35% (Cohort A) and 140 with LVEF 41%–55% (Cohort B) will be randomized 1:1:1:1 to three once daily oral doses of AZD5462 or placebo for 24 weeks. Primary endpoints are changes in end-systolic volume index (Cohort A) and systemic vascular resistance index (Cohort B) after 24 weeks. Secondary endpoints include changes in echocardiographic parameters, health status, cardiorenal biomarkers and pharmacokinetics. The safety of AZD5462 will be monitored throughout the study.

Discussion

This study will evaluate AZD5462 as a novel oral therapy for patients with chronic HF, aiming to improve symptoms as well as haemodynamic and cardiorenal biomarkers. The findings may provide insights on the development of AZD5462 in a future Phase 3 trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeVentricular Function, LeftReceptors, PeptideHumansDouble-Blind MethodAdministration, OralFemaleChronic DiseaseMaleTreatment OutcomeDose-Response Relationship, DrugRelaxinEchocardiographyMiddle AgedFollow-Up Studies

Stichwörter der Autor:innen

End-systolic volume index (ESVI)Heart failurePhase 2 trialRXFP1 agonistRelaxinSystemic vascular resistance index (SVRI)

Substanzen

RelaxinReceptors, Peptide

Autor:innen und Institutionen

  • Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Biometrics, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
  • Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • BioPharmaceuticals Clinical Operations, R&D, AstraZeneca, Cambridge, UK.

ORCID-Profile: Jaya B Rosenmeier

Förderung

  • AstraZeneca

Zitieren

APA

Quintana-Hayashi, M. P., Connolly, K., Millegård, M., Bhattacharya, C., Åstrand, M., Turton, M., Pizzato, P. E., Januzzi, J. L., & Rosenmeier, J. B. (2026). Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design. ESC Heart Failure. https://doi.org/10.1093/eschf/xvaf007

Vancouver

Quintana-Hayashi MP, Connolly K, Millegård M, Bhattacharya C, Åstrand M, Turton M, et al. Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design. ESC Heart Failure. 2026. doi:10.1093/eschf/xvaf007

BibTeX
@article{QuintanaHayashi2026,
  author = {Quintana-Hayashi, Macarena P and Connolly, Kathleen and Millegård, Marcus and Bhattacharya, Chandrali and Åstrand, Magnus and Turton, Michelle and Pizzato, Patricia Ely and Januzzi, James L and Rosenmeier, Jaya B},
  title = {Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design},
  journal = {ESC Heart Failure},
  year = {2026},
  doi = {10.1093/eschf/xvaf007}
}
Kostenlos starten →